DE69229598D1 - Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden - Google Patents
Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schädenInfo
- Publication number
- DE69229598D1 DE69229598D1 DE69229598T DE69229598T DE69229598D1 DE 69229598 D1 DE69229598 D1 DE 69229598D1 DE 69229598 T DE69229598 T DE 69229598T DE 69229598 T DE69229598 T DE 69229598T DE 69229598 D1 DE69229598 D1 DE 69229598D1
- Authority
- DE
- Germany
- Prior art keywords
- nmda receptor
- neuronal damage
- mediated neuronal
- mammal
- receptor complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68896591A | 1991-04-19 | 1991-04-19 | |
PCT/US1992/003196 WO1992018112A1 (en) | 1991-04-19 | 1992-04-17 | Method of preventing nmda receptor complex-mediated neuronal damage |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69229598D1 true DE69229598D1 (de) | 1999-08-19 |
DE69229598T2 DE69229598T2 (de) | 1999-11-04 |
Family
ID=24766524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69229598T Expired - Lifetime DE69229598T2 (de) | 1991-04-19 | 1992-04-17 | Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden |
Country Status (7)
Country | Link |
---|---|
US (1) | US5234956A (de) |
EP (1) | EP0581856B1 (de) |
JP (2) | JPH06506690A (de) |
AT (1) | ATE182076T1 (de) |
DE (1) | DE69229598T2 (de) |
ES (1) | ES2134804T3 (de) |
WO (1) | WO1992018112A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721365A (en) * | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US6071876A (en) * | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
US5910316A (en) * | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
US5691423A (en) * | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
PT669929E (pt) * | 1992-11-13 | 2007-04-30 | Immunex Corp | Ligando de elk, uma citoquina |
DE4305881C1 (de) * | 1993-02-26 | 1994-03-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung |
US5475007A (en) * | 1993-05-28 | 1995-12-12 | The Regents Of The University Of California | 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof |
US5840759A (en) * | 1993-10-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents |
WO1995010267A1 (en) * | 1993-10-08 | 1995-04-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
CA2132690A1 (en) * | 1994-09-22 | 1996-03-23 | Dean Willis | Control and modulation of inflammatory response in humans in need of such control and modulation |
US6066333A (en) * | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
US6310052B1 (en) | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
US20050137191A1 (en) * | 1996-06-04 | 2005-06-23 | Thatcher Gregory R. | Nitrate esters and their use for mitigating cellular damage |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
JPH11217330A (ja) * | 1998-01-30 | 1999-08-10 | Sumitomo Pharmaceut Co Ltd | 神経栄養因子分泌促進剤 |
US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
AR046314A1 (es) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
AU2005328701B2 (en) | 2004-06-17 | 2009-08-13 | Merz Pharma Gmbh & Co. Kgaa | Drinkable immediate release tablet made with direct compression of memantine or neramexane |
EP2111858A1 (de) | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Neue Behandlung für Morbus Alzheimer |
WO2009152479A1 (en) * | 2008-06-12 | 2009-12-17 | University Of Alabama Huntsville | Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases of trauma |
WO2009152483A2 (en) * | 2008-06-12 | 2009-12-17 | University Of Alabama Huntsville | Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma |
AR080024A1 (es) | 2010-01-27 | 2012-03-07 | Takeda Pharmaceutical | Agentes para suprimir sintomas neurologicos originados por desorden nervioso periferico inducido por agentes anticancerigenos |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
US20130323222A1 (en) | 2012-06-04 | 2013-12-05 | Matthew Charles | Human tissue kallikrein 1 glycosylation isoforms |
AU2018230478A1 (en) | 2017-03-09 | 2019-09-12 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
WO1991002810A1 (en) * | 1989-08-09 | 1991-03-07 | The Children's Medical Center Corporation | Nmda oxidizing agents for protecting neurons from injury |
US5091391A (en) * | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
-
1992
- 1992-04-17 JP JP4510067A patent/JPH06506690A/ja active Pending
- 1992-04-17 WO PCT/US1992/003196 patent/WO1992018112A1/en active IP Right Grant
- 1992-04-17 ES ES92910911T patent/ES2134804T3/es not_active Expired - Lifetime
- 1992-04-17 AT AT92910911T patent/ATE182076T1/de active
- 1992-04-17 DE DE69229598T patent/DE69229598T2/de not_active Expired - Lifetime
- 1992-04-17 EP EP92910911A patent/EP0581856B1/de not_active Expired - Lifetime
- 1992-09-22 US US07/949,342 patent/US5234956A/en not_active Expired - Lifetime
-
2005
- 2005-12-16 JP JP2005362538A patent/JP2006117693A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2006117693A (ja) | 2006-05-11 |
JPH06506690A (ja) | 1994-07-28 |
EP0581856A1 (de) | 1994-02-09 |
DE69229598T2 (de) | 1999-11-04 |
EP0581856B1 (de) | 1999-07-14 |
ES2134804T3 (es) | 1999-10-16 |
ATE182076T1 (de) | 1999-07-15 |
US5234956A (en) | 1993-08-10 |
EP0581856A4 (de) | 1994-03-02 |
WO1992018112A1 (en) | 1992-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69229598D1 (de) | Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden | |
LU90856I2 (fr) | Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables | |
AU5348194A (en) | Method of preventing nmda receptor complex-mediated neuronal damage | |
AR038434A2 (es) | Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina | |
ATE128143T1 (de) | 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung. | |
CA2002859A1 (en) | Method of treating epithelial disorders | |
ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
ES2055406T3 (es) | Composicion para el tratamiento de la inflamacion. | |
FI953899A (fi) | Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi | |
SE8202380L (sv) | Analgetisk komposition | |
NO923200L (no) | Piperidin-derivater | |
IT1247509B (it) | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus | |
DK0613687T3 (da) | Anvendelse af pregnanderivat til behandling af tumorer | |
MX9303933A (es) | Compuestos intermedios sinteticos novedosos y procedimiento para la preparacion de los derivados de los aminoacidos. | |
ES2187534T3 (es) | Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida. | |
ES2084878T3 (es) | Sal colina de diclofenac, un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
DE69104220T2 (de) | Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten. | |
ES2052670T3 (es) | Utilizacion de derivados de 2-pirimidinil-1-piperazina. | |
TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
PT95118A (pt) | Metodo para o tratamento de dependencias quimicas utilizando sertralina | |
AR011178A1 (es) | Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto | |
DK0379308T3 (da) | Fremgangsmåde til selektivt at blokere 5HT2 receptorer | |
DE69215511D1 (de) | Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen | |
TW207496B (en) | Pharmaceutical composition for preventing or delaying the occurrence of dementia | |
SE9501773D0 (sv) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R071 | Expiry of right |
Ref document number: 581856 Country of ref document: EP |